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A pneumococcal conjugate vaccine (PCV7) was intro-
duced into the United Kingdom’s childhood immu-
nisation schedule in September 2006. Evaluation of 
its impact on the incidence of invasive pneumococ-
cal disease (IPD) as assessed by routine reports of 
laboratory-confirmed cases should take into account 
possible long-term trends due to factors like changes 
in case ascertainment. To this end, we compared pre-
PCV7 trends in reported IPD incidence in England and 
Wales identified by blood culture with those for two 
other bacteraemias, Escherichia coli and non -pyogenic 
streptococci, for which there has not been any public 
health intervention. While no trend was detected in 
the age group 65 years and older, there was an annual 
increase of 3% and 11% in those aged under five years 
and between five and 64 years, respectively, which 
was similar for IPD and the other two pathogens. After 
PCV7 introduction, a continuing trend was only found 
for non-pyogenic streptococci in under five year-olds. 
These trends in the incidence for bacteraemias for 
which there has been no intervention could suggest 
that there have been changes in case ascertainment 
because of increased reporting or blood culturing. 
Accounting for them will improve the evaluation of the 
impact of PCV7 on IPD.
Introduction
Streptococcus pneumoniae, also called pneumococcus, 
is a common cause of mortality and morbidity world-
wide. It causes a variety of disease presentations, the 
most serious, invasive pneumococcal disease (IPD), 
associated with spread via the blood stream resulting 
in septicaemia, meningitis, bacteraemic pneumonia or 
invasion of other normally sterile sites such as pleural 
or synovial fluid. A seven-valent pneumococcal con-
jugate vaccine (PCV7) became available in the United 
States in 2000 offering protection against both car-
riage [1,2] and disease [3] from the seven most com-
mon serotypes causing IPD in children in developed 
countries. In September 2006 PCV7 was introduced 
into the immunisation schedule in the United Kingdom 
as a 2/4/13 month routine schedule (one dose at two 
and four months plus a booster dose at 13 months of 
age) with a catch-up for children up to two years of age. 
Most pneumococcal surveillance systems focus on IPD 
and have shown large reductions in the numbers of 
cases infected with vaccine-type strains (VT cases) in 
the targeted age groups, irrespective of vaccine sched-
ule [4,5]. However differences have been reported 
between countries in the percentage reduction of VT 
disease and the induced herd effect in older age groups 
as well as in non-vaccine-type (NVT) replacement dis-
ease. Comparison of the incidences of VT and NVT IPD 
cases before and after the introduction of PCV7 implic-
itly assumes that the reported disease incidence in the 
absence of vaccination has not changed, that a similar 
level of ascertainment has been maintained, and that 
there were no secular trends in individual serotypes. A 
recent World Health Organization (WHO) meeting that 
reviewed the post-PCV7 experience in different coun-
tries identified changes in the sensitivity of the surveil-
lance systems due to alterations in clinical awareness, 
reporting techniques and blood culturing practice as 
Figure 1
Age distribution of invasive pneumococcal disease and 
control infections, England and Wales, 2001/02 to 2005/06
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potential important confounders when making such 
comparisons over time and between countries [6].
Given the severity of IPD and the continuing universal 
access to the National Health System (NHS) it is rea-
sonable to assume that care seeking behaviour of IPD 
patients in England and Wales has remained constant 
in recent years. However, this might not be the case for 
laboratory investigation or reporting behaviour which 
may have been subject to changes in practice over 
time. Reporting rates for IPD in hospitalised cases have 
been shown to vary with blood culturing rates which 
may have changed as clinical practice has evolved 
[7], while recent technical developments may have 
improved reporting of laboratory-confirmed cases [8].
In order to interpret changes in the incidence of IPD 
after the introduction of PCV7 into the routine child-
hood vaccination scheme in England and Wales we 
assessed trends in reported IPD cases before introduc-
tion of PCV7 and related them to changes observed 
before and after that date in a control group of patho-
gens that similarly depend on blood culturing practice 
and reporting, but for which there have been no public 
health or other interventions. Our findings are relevant 
to the evaluation of the impact of PCV7 in England and 
Wales.
Methods
Pathogens
Control pathogens selected for the comparison with 
IPD were those of the most commonly reported bacter-
aemias that fulfilled the following inclusion criteria: (i) 
endemic in England and Wales and not solely outbreak-
related, (ii) not influenced by vaccination or any other 
interventions during the time period of the comparison, 
(iii) sufficiently common to provide statistically robust 
numbers in each age group, (iv) mainly diagnosed 
through blood culture. The two pathogens identified 
that fulfilled these criteria were Escherichia coli and 
non-pyogenic streptococci (Streptococcus acidomin-
imus, S. bovis, S. gordonii, S. intermedius, S. mitis, S. 
mutans, S. oralis, S. parasanguinis, S. salivarius, and 
not further typable: alpha-haemolytic Streptococcus 
sp., non-haemolytic Streptococcus sp., S. anginosus 
group, S. milleri group, S. mitis group, S. sanguinis 
group). 
Data on all infections reported between July 2000 and 
June 2010 (between 2000 and 2007 for pneumococcus) 
and identified by blood culture were obtained from 
the national routine laboratory surveillance system of 
England and Wales (LabBase) [8]. Only one isolate per 
disease episode was included in the analysis. More 
than one isolate from the same person where the inter-
val between specimens was less than 14 days and the 
same pathogen was isolated were assumed to repre-
sent the same illness episode. As part of the enhanced 
surveillance [9] episodes of IPD were checked for dupli-
cates using personal identifiers.
Figure 2
Pre-PCV7 trends in invasive pneumococcal disease and 
control infections stratified by age groups, England and 
Wales, 2000/01–2005/06
PCV7: seven-valent pneumococcal vaccine.
For the ease of comparison trends for all pathogens are plotted 
after scaling by the respective average incidence. 
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Statistical analysis
For each of the pathogens a negative binomial regres-
sion model was fitted to the observed number of cases 
per 100,000 population. We regressed the number of 
cases with a linear trend and a five-level factor to indi-
cate the period before and the four seasons after PCV7 
introduction, 2006/07, 2007/08, 2008/09, 2009/10 
and included a population offset. The (anti-logged) 
slope of this model indicates the pre-PCV7 trend, i.e. 
a slope >1 indicates a positive trend and a slope <1 a 
negative trend in a negative binomial model. To test for 
differences in slopes we tested their confidence inter-
vals for overlap which provides conservative estimates 
[10]. Each of the post-PCV7 factors indicates the devia-
tion of the post-2005/06 data from the extrapolated 
pre-2005/06 trend. No adjustment for multiple com-
parisons was made.
Data for all analyses were stratified into three age 
groups (<5, 5–64, ≥65 years) with missing age informa-
tion being imputed from the age distribution observed 
for the pathogens, and were performed in R version 
2.11 [11].
Results
More than 150,000 disease episodes before PCV7 
introduction were considered. They were differently 
distributed amongst the age groups (Figure1). While 
IPD and non-pyogenic streptococci showed similar 
patterns, most of the E. coli episodes were reported 
in the elderly population. In the population under five 
years of age 27% of disease episodes were due to E. 
coli, 49% to IPD and 25% to non-pyogenic streptococci. 
In the 5–64 year-olds the respective distribution was 
50%, 34% and 16%, and for those 65 years and older it 
was 70%, 21% and 9%.
The regression model found a positive trend in IPD 
incidence prior to the introduction of PCV7 in the age 
groups under five years and between five and 64 years. 
The trend was most pronounced in the 5–64 year-olds 
with an average yearly increase of about 11% (p<0.001). 
In the under five year-olds reports of IPD increased 
about 3% per year (p=0.031). In the over 65 year-olds 
we estimated this trend to be not significantly different 
from zero (p=0.91) (Table 1). 
Table 1
Estimated slopes in models of the pre-PCV7 trend in invasive pneumococcal disease and control infections, England and 
Wales, 2000/01–2005/06
Age group Invasive pneumococcal disease slope [95% CI]
Escherichia coli
slope [95% CI]
Non-pyogenic streptococci
slope [95% CI]
<5 years 1.030 [1.002–1.058] 1.091 [1.052–1.132] 1.093[1.051–1.138]
5-64 years 1.106 [1.075–1.138] 1.095 [1.075–1.114] 1.097 [1.061–1.134]
≥65 years 0.999 [0.972–1.027] 1.074 [1.055–1.193] 1.087 [1.063–1.111]
CI: confidence interval; PCV7: seven-valent pneumococcal vaccine.
Table 2
Percentage difference between the incidence of control infections and the incidence predicted by two different models, 
England and Wales, 2000/01–2008/09
Age group Season
Escherichia coli Non-pyogenic streptococci
Model Aa Model B Model A Model B
<5 years 2006/07 -15.5% [-27.2 to -2.0] -8.1% -16.7% [-27.2 to -2.0] -9.2%
2007/08 -13.8% [-26.8 to 1.6] 5.1% -5.2% [-19.6 to 11.8] 15.9%
2008/09 -19.5% [-33 to -3.2] 8.7% -8.3% [-23.9 to 10.4] 24.3%
2009/10  -25.5% [-39.4 to -8.4] 9.5% -17.3% [-32.9 to 2.0] 22.3%
5-64 years 2006/07 -7.4% [-14.1 to -0.2] 4.4% -10.9% [-22.5to 2.6] 0.7%
2007/08 -5.9% [-13.4 to 2.4] 15.9% -15.8% [-28.0 to -1.5] 4.0%
2008/09 -12.3% [-20.1 to -3.6] 18.0% -23.1% [-35.6 to -8.3] 3.9%
2009/10 -16.1% [-24.4 to -6.8] 23.3% -31.9% [-44.1 to -17.1] -0.8%
≥65 years 2006/07 -8.6% [-15.4 to -1.3] 2.3% -11.1% [-18.7 to -2.8] 0.7%
2007/08 -8.3% [-15.9 to 0.0] 10.8% -7.5% [-16.2 to 2.1] 14.3%
2008/09 -12.2% [-20.3 to -3.3] 15.0% -18.0% [-26.7 to -8.3] 11.0%
2009/10 -11.9% [-20.9 to -1.9] 25.2% -25.0% [-33.8 to -15.0] 11.5%
PCV7: seven-valent pneumococcal vaccine.
Model A: extrapolation of the trend in the period before introduction of PCV7.
Model B: assuming the trend to discontinue from the season 2005/06 onwards.
a For model A 95% confidence intervals are presented.
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For E. coli and non-pyogenic streptococci the trends 
were significantly positive in all age groups (all 
p<0.001). Pre-PCV7 trends in IPD were not significantly 
different from those in E. coli and non-pyogenic strep-
tococci (Table 1) in the under 65 year-olds, although in 
the children trends in IPD were slightly smaller than in 
the other pathogens (Table 1, Figure 2). However, in the 
age group 65 years and older no significantly positive 
trend was found for IPD, while reports for E. coli and 
non-pyogenic streptococci increased by 7–9% per year.
In the youngest age group (under five years of age) 
the reported incidence of non-pyogenic streptococci 
closely followed the prediction extrapolated from the 
trend before the season 2006/07 (Figure 3). However, 
the prediction for E. coli significantly overestimated 
the actual incidence (Table 2) although the reported 
incidences were still higher then before the date of 
PCV7 introduction. In the 5–64 year-olds the pre-PCV7 
trend of non-pyogenic streptococci diminished in the 
seasons after introduction of PCV7 and the incidence 
remained at the level of the incidence observed in the 
season 2005/06. Again E. coli differed: the observed 
incidences were in between the predictions that 
assumed the pre-PCV7 to continue and those assum-
ing no trend after introduction of PCV7. In the oldest 
age group the reports for both E. coli and non-pyogenic 
streptococci were in between these two prediction 
scenarios. 
Discussion and conclusion
Upward trends in the annual numbers of some bacter-
aemias have been reported previously [12]. The similar-
ity of the trends for IPD and the two control pathogens 
in the age groups under 65 years before 2005/06 sug-
gests that the sensitivity of the national surveillance 
system in England and Wales was increasing prior to 
introduction of PCV7. While the trends for the control 
pathogens extrapolated from the period before PCV7 
introduction were not entirely consistent with the 
observed incidence in the period after 2005/06, they 
may nevertheless provide an equally likely indication 
of the expected numbers of bacteraemia reports in 
the post-PCV7 period compared to those assuming the 
trend to discontinue after 2005/06.
The data sources introduced some limitations to our 
analysis. While we employed the data from the national 
Figure 3
Pre-and post-PCV7 trends in control infections stratified by pathogen and age group, England and Wales, 2000/01–2008/09
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laboratory-based surveillance for E. coli and non-pyo-
genic streptococci the data on S. pneumoniae was 
further enhanced and controlled for duplicates due 
to inconsistencies specific to IPD in the national lab-
oratory-based surveillance dataset in the years 2002 
and 2003 when duplicates had been included in error; 
such duplicates were removed from the enhanced IPD 
dataset (which contains an extra 10–20% of cases 
identified solely from referral of isolates for serotyp-
ing). A further limitation which may have affected the 
data was the migration in mid-2001 of the national 
surveillance database to a new platform which could 
have caused inconsistencies for all pathogens if data 
deduplication was compromised. Non-pyogenic strep-
tococci are sometimes associated with contamination. 
This could artificially increase the reported incidence 
of bacteraemias caused by non-pyogenic streptococci. 
However, this is unlikely to alter the trend estimates for 
increasing ascertainment since these would be equally 
reflected by the contaminated samples.
We assessed the goodness of fit of the regression mod-
els in the pre-PCV7 era (goodness of fit is not an issue 
for the post PCV7 period since the model is saturated 
there, i.e. the model is set up to exactly fit the data). 
For all six models (three age groups for both E. coli and 
non-pyogenic streptococci) the root mean square error 
was between 1.29 and 1.34. Also, considering the loga-
rithm of time rather than time as a linear variable did 
not improve the Akaike information criterion.
Secular trends in the reports of laboratory-con-
firmed IPD in the absence of vaccination have been 
observed for some serotypes [13,14]. These trends 
are poorly understood, cannot be predicted and are 
likely to affect the estimates of the vaccine impact. 
However, in the younger age groups our pre-PCV7 
trend estimates for IPD and the other pathogens were 
similar, which suggest that these trends were more 
pronounced in that period than any pathogen-specific 
secular trends. 
The similar trends prior to 2005/06 between pneu-
mococcus and the other pathogens in the age groups 
under five years and between five and 64 years could 
reveal a common source causing this trend; increasing 
ascertainment of cases. This could be due to numerous 
reasons including increasing blood culturing practice 
and an increasing number of laboratories choosing to 
report these non-notifiable diseases to the national 
database. Additional factors might have contributed 
to the observed trends, such as increasing automa-
tion of detection techniques or improved survival of 
people with underlying conditions, which could have 
increased the numbers of vulnerable people in the 
population. However, in the population aged 65 years 
and older, the trends in IPD were different from the 
other pathogens. This could possibly be attributed to 
the step-wise introduction of a vaccination programme 
with the 23-valent pneumococcal polysaccharide vac-
cine (PPV) from August 2003 for this age group. A 
detailed evaluation of the effectiveness of PPV in the 
elderly and the likely impact of the universal vaccina-
tion programme for this age group is currently being 
undertaken by the Health Protection Agency.
To assess the probable development of reported cases 
of IPD in the absence of vaccination we compared two 
predictions, continuing pre-PCV7 trend (Model A) and 
no trend (Model B), to the actual reports for E. coli and 
non-pyogenic streptococci. Although we have no clear 
evidence that one of the predictions was more cor-
rect than the other, the reported number of cases was 
in between both predictions in all age groups. While 
Model A might provide the better prediction for the 
under five year-olds, Model B seemed to provide more 
reliable estimates in the age group between five and 
64 years. 
These findings do have important implications for 
analysing the effect of the introduction of PCV7 to 
the childhood immunisation scheme: We find that by 
ignoring the pre-PCV7 trend, one is likely to underesti-
mate the reduction in IPD and overestimate the degree 
of replacement disease. However, allowing for trends 
introduces the risk to overestimate the reduction in VT 
IPD and underestimate possible replacement especially 
in the 5–64 year-olds. This analysis helps to estimate 
the uncertainty introduced by changing ascertainment 
when analysing the effects of PCV in England and 
Wales. Similar analyses from other countries would be 
valuable to improve the comparability of the vaccine 
effects.
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